Molecular pathogenesis of hepatocellular carcinoma: New therapeutic approaches and predictive pathology;Molekulare pathogenese des hepatozellulären karzinoms: Ansatzpunkte für neue therapien und prädiktive pathologie

Pathologe

Volumn 28, Issue 4, 2007, Pages 261-268

  Kern, M A ^a   Breuhahn, K ^a   Schuchmann, M ^b   Schirmacher, P ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Carcinogenesis; Hepatocellular carcinoma; Liver cirrhosis; Tumor progression

Indexed keywords

CANCER GROWTH; CANCER INCIDENCE; DIAGNOSTIC APPROACH ROUTE; DIAGNOSTIC TEST; HUMAN; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; REVIEW;

CARCINOMA, HEPATOCELLULAR; CYCLOOXYGENASE 2; DISEASE PROGRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, P53; HEPATOCYTE GROWTH FACTOR; HUMANS; LIVER NEOPLASMS; PROTO-ONCOGENE PROTEINS C-KIT;

EID: 34447274726     PISSN: 01728113     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00292-007-0890-1     Document Type: Review

References (130)

1. International Working Party (1995) Terminology of nodular hepatocellular lesions. Hepatology 22: 83-993
2. Aihara T, Noguchi S, Sasaki Y et al. (1996) Clonal analysis of precancerous lesion of hepatocellular carcinoma. Gastroenterology 111: 455-461
3. Allgaier HP, Deibert P, Olschewski M et al. (1998) Survival benefit of patients with inoperable hepatocellular carcinoma treated by a combination of transarterial chemoembolization and percutaneous ethanol injection - a single-center analysis including 132 patients. Int J Cancer 79: 601-605
4. Andrisani OM, Barnabas S (1999) The transcriptional function of the hepatitis B virus X protein and its role in hepatocarcinogenesis (Review). Int J Oncol 15: 373-379
5. Arima N, Kao CY, Licht T et al. (2001) Modulation of cell growth by the hepatitis C virus nonstructural protein NS5A. J Biol Chem 276: 12675-12684
6. Arteaga C (2003) Targeting HER1/EGFR: a molecular approach to cancer therapy. Semin Oncol 30: 3-14
7. Balsano C, Avantaggiati ML, Natoli G et al. (1991) Full-length and truncated versions of the hepatitis B virus (HBV) X protein (pX) transactivate the cmyc protooncogene at the transcriptional level. Biochem Biophys Res Commun 176: 985-992
8. Baselga J, Averbuch SD (2000) ZD1839 (Iressa') as an anticancer agent. Drugs 60 Suppl 1: 33-40; discussion 41-32
9. Berthou S, Aebersold DM, Schmidt LS et al. (2004) The Met kinase inhibitor SU11274 exhibits a selective inhibition pattern toward different receptor mutated variants. Oncogene 23: 5387-5393
10. Blum G, Gazit A, Levitzki A (2003) Development of new insulin-like growth factor-1 receptor kinase inhibitors using catechol mimics. J Biol Chem 278: 40442-40454
11. Bosch FX, Ribes J, Cleries R, Diaz M (2005) Epidemiology of hepatocellular carcinoma. Clin Liver Dis 9: 191-211
12. Breuhahn K, Baeuerle PA, Peters M et al. (2005) Expression of epithelial cellular adhesion molecule (Ep-CAM) in chronic (necro-)inflammatory liver diseases and hepatocellular carcinoma. Hepatol Res (Epub ahead of print)
13. Breuhahn K, Vreden S, Haddad R et al. (2004) Molecular profiling of human hepatocellular carcinoma defines mutually exclusive interferon regulation and insulin-like growth factor II overexpression. Cancer Res 64: 6058-6064
14. Brodt P, Samani A, Navab R (2000) Inhibition of the type I insulin-like growth factor receptor expression and signaling: novel strategies for antimetastatic therapy. Biochem Pharmacol 60: 1101-1107
15. Bruix J (1997) Treatment of hepatocellular carcinoma. Hepatology 25: 259-262
16. Bruix J, Boix L, Sala M, Llovet JM (2004) Focus on hepatocellular carcinoma. Cancer Cell 5: 215-219
17. Buckbinder L, Talbott R, Velasco-Miguel S et al. (1995) Induction of the growth inhibitor IGF-binding protein 3 by p53. Nature 377: 646-649
18. Cariani E, Lasserre C, Seurin D et al. (1988) Differential expression of insulin-like growth factor II mRNA in human primary liver cancers, benign liver tumors, and liver cirrhosis. Cancer Res 48: 6844-6849
19. Castells A, Bruix J, Bru C et al. (1995) Treatment of hepatocellular carcinoma with tamoxifen: a double-blind placebo-controlled trial in 120 patients. Gastroenterology 109: 917-922
20. Chen BH, Xie Q, Liu KD (2003) [Influence of the inhibitor of c-Met on the growth and motility of hepatocellular carcinoma cells]. Zhonghua Gan Zang Bing Za Zhi 11: 487-489
21. Christensen JG, Schreck R, Burrows J et al. (2003) A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo. Cancer Res 63:7345-7355
22. Chung CY, Yeh KT, Hsu NC et al. (2005) Expression of c-kit protooncogene in human hepatocellular carcinoma. Cancer Lett 217: 231-236
23. Cohen BD, Baker DA, Soderstrom C et al. (2005) Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871. Clin Cancer Res 11: 2063-2073
24. Cohen PS, Chan JP, Lipkunskaya M et al. (1994) Expression of stem cell factor and c-kit in human neuroblastoma. The Children's Cancer Group. Blood 84: 3465-3472
25. D'Errico A, Fiorentino M, Ponzetto A et al. (1996) Liver hepatocyte growth factor does not always correlate with hepatocellular proliferation in human liver lesions: its specific receptor c-met does. Hepatology 24: 60-64
26. Daveau M, Scotte M, Francois A et al. (2003) Hepatocyte growth factor, transforming growth factor alpha, and their receptors as combined markers of prognosis in hepatocellular carcinoma. Mol Carcinog 36: 130-141
27. De Souza AT, Hankins GR, Washington MK et al. (1995) M6P/IGF2R gene is mutated in human hepatocellular carcinomas with loss of heterozygosity. Nat Genet 11: 447-449
28. Di Paolo C, Willuda J, Kubetzko S et al. (2003) A recombinant immunotoxin derived from a humanized epithelial cell adhesion molecule-specific single-chain antibody fragment has potent and selective antitumor activity. Clin Cancer Res 9: 2837-2848
29. Donato F, Boffetta P, Puoti M (1998) A meta-analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma. Int J Cancer 75: 347-354
30. Eckel F, von Delius S, Mayr M et al. (2005) Pharmacokinetic and clinical phase ii trial of imatinib in patients with impaired liver function and advanced hepatocellular carcinoma. Oncology 69: 363-371
31. El-Serag HB (2002) Hepatocellular carcinoma: an epidemiologic view. J Clin Gastroenterol 35: S72-S78
32. El-Serag HB (2004) Hepatocellular carcinoma: recent trends in the United States. Gastroenterology 127: S27-S34
33. El-Serag HB, Mason AC (1999) Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 340: 745-750
34. El-Serag HB, Mason AC, Key C (2001) Trends in survival of patients with hepatocellular carcinoma between 1977 and 1996 in the United States. Hepatology 33: 62-65
35. Foulstone E, Prince S, Zaccheo O et al. (2005) Insulin-like growth factor ligands, receptors, and binding proteins in cancer. J Pathol 205: 145-153
36. Garber K (2005) IGF-1: old growth factor shines as new drug target. J Natl Cancer Inst 97: 790-792
37. Ghosh AK, Majumder M, Steele R et al. (2000) Hepatitis C virus NS5A protein protects against TNF-alpha mediated apoptotic cell death. Virus Res 67: 173-178
38. Girnita A, Girnita L, del Prete F et al. (2004) Cyclolignans as inhibitors of the insulin-like growth factor-1 receptor and malignant cell growth. Cancer Res 64: 236-242
39. Gong Y, Cui L, Minuk GY (2000) The expression of insulin-like growth factor binding proteins in human hepatocellular carcinoma. Mol Cell Biochem 207: 101-104
40. Graef E, Caselmann WH, Wells J, Koshy R (1994) Insertional activation of mevalonate kinase by hepatitis B virus DNA in a human hepatoma cell line. Oncogene 9: 81-87
41. Guirouilh J, Castroviejo M, Balabaud C et al. (2000) Hepatocarcinoma cells stimulate hepatocyte growth factor secretion in human liver myofibroblasts. Int J Oncol 17: 777-781
42. Heideman DA, Overmeer RM, van Beusechem VW et al. (2005) Inhibition of angiogenesis and HGF-cMET-elicited malignant processes in human hepatocellular carcinoma cells using adenoviral vector-mediated NK4 gene therapy. Cancer Gene Ther 12: 954-962
43. Hopfner M, Sutter AP, Huether A et al. (2004) Targeting the epidermal growth factor receptor by gefitinib for treatment of hepatocellular carcinoma. J Hepatol 41: 1008-1016
44. Hov H, Holt RU, Ro TB et al. (2004) A selective c-met inhibitor blocks an autocrine hepatocyte growth factor growth loop in ANBL-6 cells and prevents migration and adhesion of myeloma cells. Clin Cancer Res 10: 6686-6694
45. Hsu C, Huang CL, Hsu HC et al. (2002) HER-2/neu overexpression is rare in hepatocellular carcinoma and not predictive of anti-HER-2/neu regulation of cell growth and chemosensitivity. Cancer 94: 415-420
46. Hu KQ, Yu CH, Vierling JM (1992) Up-regulation of intercellular adhesion molecule 1 transcription by hepatitis B virus X protein. Proc Natl Acad Sci U S A 89: 11441-11445
47. Huether A, Hopfner M, Baradari V et al. (2005) EGFR blockade by cetuximab alone or as combination therapy for growth control of hepatocellular cancer. Biochem Pharmacol 70: 1568-1578
48. Huether A, Hopfner M, Sutter AP et al. (2005) Erlotinib induces cell cycle arrest and apoptosis in hepatocellular cancer cells and enhances chemosensitivity towards cytostatics. J Hepatol 43: 661-669
49. Huynh H, Chow PK, Ooi LL, Soo KC (2002) A possible role for insulin-like growth factor-binding protein-3 autocrine/paracrine loops in controlling hepatocellular carcinoma cell proliferation. Cell Growth Differ 13: 115-122
50. Ikeda M, Okusaka T, Ueno H et al. (2005) A phase II trial of continuous infusion of 5-fluorouracil, mitoxantrone, and cisplatin for metastatic hepatocellular carcinoma. Cancer 103: 756-762
51. Itoh T, Shiro T, Seki T et al. (2000) Relationship between p53 overexpression and the proliferative activity in hepatocellular carcinoma. Int J Mol Med 6: 137-142
52. Jeng KS, Sheen IS, Chen BF, Wu JY (2000) Is the p53 gene mutation of prognostic value in hepatocellular carcinoma after resection? Arch Surg 135: 1329-1333
53. Jeng YM, Lin CY, Hsu HC (2000) Expression of the c-kit protein is associated with certain subtypes of salivary gland carcinoma. Cancer Lett 154: 107-111
54. Kanai F, Shiratori Y, Yoshida Y et al. (1996) Gene therapy for alpha-fetoprotein-producing human hepatoma cells by adenovirus-mediated transfer of the herpes simplex virus thymidine kinase gene. Hepatology 23: 1359-1368
55. Kern JA, Schwartz DA, Nordberg JE et al. (1990) p185neu expression in human lung adenocarcinomas predicts shortened survival. Cancer Res 50: 5184-5187
56. Kern MA, Breuhahn K, Schirmacher P (2002) Molecular pathogenesis of human hepatocellular carcinoma. Adv Cancer Res 86: 67-112
57. Kern MA, Schoneweiss MM, Sahi D et al. (2004) Cyclooxygenase-2 inhibitors suppress the growth of human hepatocellular carcinoma implants in nude mice. Carcinogenesis 25: 1193-1199
58. Kern MA, Schubert D, Sahi D et al. (2002) Proapoptotic and antiproliferative potential of selective cyclooxygenase-2 inhibitors in human liver tumor cells. Hepatology 36: 885-894
59. Khuri FR, Nemunaitis J, Ganly I et al. (2000) A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med 6: 879-885
60. Kira S, Nakanishi T, Suemori S et al. (1997) Expression of transforming growth factor alpha and epidermal growth factor receptor in human hepatocellular carcinoma. Liver 17: 177-182
61. Ko YJ, Bubley GJ, Weber R et al. (2004) Safety, pharmacokinetics, and biological pharmacodynamics of the immunocytokine EMD 273066 (huKS-IL2): results of a phase I trial in patients with prostate cancer. J Immunother 27: 232-239
62. Koga H, Sakisaka S, Ohishi M et al. (1999) Expression of cyclooxygenase-2 in human hepatocellular carcinoma: relevance to tumor dedifferentiation. Hepatology 29: 688-696
63. Kondo M, Yamamoto H, Nagano H et al. (1999) Increased expression of COX-2 in nontumor liver tissue is associated with shorter disease-free survival in patients with hepatocellular carcinoma. Clin Cancer Res 5: 4005-4012
64. Levine AJ (1997) p53, the cellular gatekeeper for growth and division. Cell 88: 323-331
65. Li X, Nong Z, Ekstrom C et al. (1997) Disrupted IGF2 promoter control by silencing of promoter P1 in human hepatocellular carcinoma. Cancer Res 57: 2048-2054
66. Llovet JM, Burroughs A, Bruix J (2003) Hepatocellular carcinoma. Lancet 362: 1907-1917
67. Lu YS, Hsu C, Li CC et al. (2004) Phase II study of combination doxorubicin, interferon-alpha, and high-dose tamoxifen treatment for advanced hepatocellular carcinoma. Hepatogastroenterology 51: 815-819
68. Luber B, Arnold N, Sturzl M et al. (1996) Hepatoma-derived integrated HBV DNA causes multi-stage transformation in vitro. Oncogene 12: 1597-1608
69. Lund P, Schubert D, Niketeghad F, Schirmacher P (2004) Autocrine inhibition of chemotherapy response in human liver tumor cells by insulin-like growth factor-II. Cancer Lett 206: 85-96
70. Lux ML, Rubin BP, Biase TL et al. (2000) KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors. Am J Pathol 156: 791-795
71. Mahe Y, Mukaida N, Kuno K et al. (1991) Hepatitis B virus X protein transactivates human interleukin-8 gene through acting on nuclear factor kB and CCAAT/enhancer-binding protein-like cis-elements. J Biol Chem 266: 13759-13763
72. Majumder M, Ghosh AK, Steele R et al. (2001) Hepatitis C virus NS5A physically associates with p53 and regulates p21/waf1 gene expression in a p53-dependent manner. J Virol 75: 1401-1407
73. Meden H, Kuhn W (1997) Overexpression of the oncogene c-erbB-2 (HER2/neu) in ovarian cancer: a new prognostic factor. Eur J Obstet Gynecol Reprod Biol 71: 173-179
74. Mendel DB, Laird AD, Smolich BD et al. (2000) Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent. Anticancer Drugs 15: 29-41
75. Min Y, Adachi Y, Yamamoto H et al. (2003) Genetic blockade of the insulin-like growth factor-I receptor: a promising strategy for human pancreatic cancer. Cancer Res 63: 6432-6441
76. Mitsiades CS, Mitsiades NS, McMullan CJ et al. (2004) Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell 5: 221-230
77. Miyakawa H, Izumi N, Marumo F, Sato C (1996) Roles of alcohol, hepatitis virus infection, and gender in the development of hepatocellular carcinoma in patients with liver cirrhosis. Alcohol Clin Exp Res 20: 91A-94A
78. Moinzadeh P, Breuhahn K, Stutzer H, Schirmacher P (2005) Chromosome alterations in human hepatocellular carcinomas correlate with aetiology and histological grade - results of an explorative CGH meta-analysis. Br J Cancer 92: 935-941
79. Moriya K, Fujie H, Shintani Y et al. (1998) The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nat Med 4: 1065-1067
80. Mosolits S, Markovic K, Frodin JE et al. (2004) Vaccination with Ep-CAM protein or anti-idiotypic antibody induces Th1-biased response against MHC class I- and II-restricted Ep-CAM epitopes in colorectal carcinoma patients. Clin Cancer Res 10: 5391-5402
81. Murakami Y, Hayashi K, Hirohashi S, Sekiya T (1991) Aberrations of the tumor suppressor p53 and retinoblastoma genes in human hepatocellular carcinomas. Cancer Res 51: 5520-5525
82. Nagaya T, Nakamura T, Tokino T et al. (1987) The mode of hepatitis B virus DNA integration in chromosomes of human hepatocellular carcinoma. Genes Dev 1: 773-782
83. Natoli G, Avantaggiati ML, Chirillo P et al. (1994) Induction of the DNA-binding activity of c-jun/c-fos heterodimers by the hepatitis B virus transactivator pX. Mol Cell Biol 14: 989-998
84. Naundorf S, Preithner S, Mayer P et al. (2002) In vitro and in vivo activity of MT201, a fully human monoclonal antibody for pancarcinoma treatment. Int J Cancer 100: 101-110
85. Nemunaitis J, Khuri F, Ganly I et al. (2001) Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer. J Clin Oncol 19: 289-298
86. Ng IO, Lee JM, Srivastava G, Ng M (1998) Expression of insulin-like growth factor II mRNA in hepatocellular carcinoma. J Gastroenterol Hepatol 13: 152-157
87. Noguchi O, Enomoto N, Ikeda T et al. (1996) Gene expressions of c-met and hepatocyte growth factor in chronic liver disease and hepatocellular carcinoma. J Hepatol 24: 286-292
88. Ozturk M (1999) Genetic aspects of hepatocellular carcinogenesis. Semin Liver Dis 19: 235-242
89. Park JW, Park JE, Lee JA et al. (2006) Cyclooxygenase-2 (COX-2) is directly involved but not decisive in proliferation of human hepatocellular carcinoma cells. J Cancer Res Clin Oncol 132: 184-192
90. Pennacchietti S, Michieli P, Galluzzo M et al. (2003) Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 3: 347-361
91. Philip PA, Mahoney MR, Allmer C et al. (2005) Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer. J Clin Oncol 23: 6657-6663
92. Pollack VA, Savage DM, Baker DA et al. (1999) Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice. J Pharmacol Exp Ther 291: 739-748
93. Pollak MN, Schernhammer ES, Hankinson SE (2004) Insulin-like growth factors and neoplasia. Nat Rev Cancer 4: 505-518
94. Prange W, Breuhahn K, Fischer F et al. (2003) Beta-catenin accumulation in the progression of human hepatocarcinogenesis correlates with loss of E-cadherin and accumulation of p53, but not with expression of conventional WNT-1 target genes. J Pathol 201: 250-259
95. Prange W, Schirmacher P (2001) Absence of therapeutically relevant c-erbB-2 expression in human hepatocellular carcinomas. Oncol Rep 8: 727-730
96. Ranzani GN, Pellegata NS, Previdere C et al. (1990) Heterogeneous protooncogene amplification correlates with tumor progression and presence of metastases in gastric cancer patients. Cancer Res 50: 7811-7814
97. Ray RB, Steele R, Meyer K, Ray R (1997) Transcriptional repression of p53 promoter by hepatitis C virus core protein. J Biol Chem 272: 10983-10986
98. Resnicoff M, Abraham D, Yutanawiboonchai W et al. (1995) The insulin-like growth factor I receptor protects tumor cells from apoptosis in vivo. Cancer Res 55: 2463-2469
99. Riesenberg R, Buchner A, Pohla H, Lindhofer H (2001) Lysis of prostate carcinoma cells by trifunctional bispecific antibodies (alpha EpCAM x alpha CD3). J Histochem Cytochem 49: 911-917
100. Rochester MA, Riedemann J, Hellawell GO et al. (2005) Silencing of the IGF1R gene enhances sensitivity to DNA-damaging agents in both PTEN wild-type and mutant human prostate cancer. Cancer Gene Ther 12: 90-100
101. Rusnak DW, Lackey K, Affleck K et al. (2001) The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol Cancer Ther 1: 85-94
102. Saffari B, Jones LA, el-Naggar A et al. (1995) Amplification and overexpression of HER-2/neu (c-erbB2) in endometrial cancers: correlation with overall survival. Cancer Res 55: 5693-5698
103. Schirmacher P, Held WA, Yang D et al. (1991) Selective amplification of periportal transitional cells precedes formation of hepatocellular carcinoma in SV40 large tag transgenic mice. Am J Pathol 139: 231-241
104. Schirmacher P, Held WA, Yang D et al. (1992) Reactivation of insulin-like growth factor II during hepatocarcinogenesis in transgenic mice suggests a role in malignant growth. Cancer Res 52: 2549-2556
105. Schirmacher P, Rogler CE, Dienes HP (1993) Current pathogenetic and molecular concepts in viral liver carcinogenesis. Virchows Arch B Cell Pathol Incl Mol Pathol 63: 71-89
106. Schirmacher P, Wang H, Stahnke G et al. (1995) Sequences and structures at hepadnaviral integration: recombination sites implicate topoisomerase I in hepadnaviral DNA rearrangements and integration. J Hepatol 22: 21-33
107. Schwartz JD, Beutler AS (2004) Therapy for unresectable hepatocellular carcinoma: review of the randomized clinical trials-II: systemic and local non-embolization-based therapies in unresectable and advanced hepatocellular carcinoma. Anticancer Drugs 15: 439-452
108. Scotlandi K, Benini S, Nanni P et al. (1998) Blockage of insulin-like growth factor-I receptor inhibits the growth of Ewing's sarcoma in athymic mice. Cancer Res 58: 4127-4131
109. Seol DW, Chen Q, Zarnegar R (2000) Transcriptional activation of the hepatocyte growth factor receptor (c-met) gene by its ligand (hepatocyte growth factor) is mediated through AP-1. Oncogene 19: 1132-1137
110. Shaul Y, Ziemer M, Garcia PD et al. (1984) Cloning and analysis of integrated hepatitis virus sequences from a human hepatoma cell line. J Virol 51: 776-787
111. Shiota G, Okubo M, Noumi T et al. (1999) Cyclooxygenase-2 expression in hepatocellular carcinoma. Hepatogastroenterology 46: 407-412
112. Slichenmyer WJ, Elliott WL, Fry DW (2001) CI-1033, a pan-erbB tyrosine kinase inhibitor. Semin Oncol 28: 80-85
113. Sohda T, Yun K, Iwata K et al. (1996) Increased expression of insulin-like growth factor 2 in hepatocellular carcinoma is primarily regulated at the transcriptional level. Lab Invest 75: 307-311
114. Strohmeyer T, Peter S, Hartmann M et al. (1991) Expression of the hst-1 and c-kit protooncogenes in human testicular germ cell tumors. Cancer Res 51: 1811-1816
115. Sue SR, Chari RS, Kong FM et al. (1995) Transforming growth factor-beta receptors and mannose 6-phosphate/insulin-like growth factor-II receptor expression in human hepatocellular carcinoma. Ann Surg 222: 171-178
116. Tabor E (1994) Tumor suppressor genes, growth factor genes, and oncogenes in hepatitis B virus-associated hepatocellular carcinoma. J Med Virol 42: 357-365
117. Tavian D, De Petro G, Benetti A et al. (2000) u-PA and c-MET mRNA expression is co-ordinately enhanced while hepatocyte growth factor mRNA is down-regulated in human hepatocellular carcinoma. Int J Cancer 87: 644-649
118. Tokino T, Tamura H, Hori N, Matsubara K (1991) Chromosome deletions associated with hepatitis B virus integration. Virology 185: 879-882
119. Toyota M, Hinoda Y, Takaoka A et al. (1993) Expression of c-kit and kit ligand in human colon carcinoma cells. Tumour Biol 14: 295-302
120. Trojan J, Johnson TR, Rudin SD et al. (1993) Treatment and prevention of rat glioblastoma by immunogenic C6 cells expressing antisense insulin-like growth factor I RNA. Science 259: 94-97
121. Ueno Y, Sakurai H, Matsuo M et al. (2005) Selective inhibition of TNF-alpha-induced activation of mitogen-activated protein kinases and metastatic activities by gefitinib. Br J Cancer 92: 1690-1695
122. Vernucci M, Cerrato F, Besnard N et al. (2000) The H19 endodermal enhancer is required for Igf2 activation and tumor formation in experimental liver carcinogenesis. Oncogene 19: 6376-6385
123. Wang J, Chenivesse X, Henglein B, Brechot C (1990) Hepatitis B virus integration in a cyclin A gene in a hepatocellular carcinoma. Nature 343: 555-557
124. Wang SY, Chen B, Zhan YQ et al. (2004) SU5416 is a potent inhibitor of hepatocyte growth factor receptor (c-Met) and blocks HGF-induced invasiveness of human HepG2 hepatoma cells. J Hepatol 41: 267-273
125. Wang X, Le P, Liang C et al. (2003) Potent and selective inhibitors of the Met [hepatocyte growth factor/scatter factor (HGF/SF) receptor] tyrosine kinase block HGF/SF-induced tumor cell growth and invasion. Mol Cancer Ther 2: 1085-1092
126. Went PT, Lugli A, Meier S et al. (2004) Frequent EpCam protein expression in human carcinomas. Hum Pathol 35: 122-128
127. Wodarz A, Nusse R (1998) Mechanisms of Wnt signaling in development. Annu Rev Cell Dev Biol 14: 59-88
128. Wong CM, Fan ST, Ng IO (2001) beta-Catenin mutation and overexpression in hepatocellular carcinoma: clinicopathologic and prognostic significance. Cancer 92: 136-145
129. Xian ZH, Zhang SH, Cong WM et al. (2005) Overexpression/amplification of HER-2/neu is uncommon in hepatocellular carcinoma. J Clin Pathol 58: 500-503
130. Yarden Y, Sliwkowski MX (2001) Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2: 127-137